Abstract 218P
Background
Adjuvant chemotherapy improved disease-free survival (DFS) among MIUC patients (pts). CheckMate 274 study demonstrated adjuvant immunotherapy improved DFS in MIUC pts. However, few studies explored the efficacy of adjuvant chemotherapy plus immunotherapy in MIUC pts. Our real-world study aimed to evaluate the effectiveness of adjuvant chemoimmunotherapy versus chemotherapy in high-risk MIUC pts.
Methods
Clinical data of high-risk MIUC pts between October 2016 and March 2023 were retrospectively collected from Sun Yat-sen University Cancer Center. After radical surgery, pT3/4 and pN+ MIUC pts without prior neoadjuvant therapy received adjuvant tislelizumab combined with GC (T+GC) or GC. In T+GC group, pts firstly received cisplatin 70 mg/m2 D2, and gemcitabine 1000 mg/m2 D1 and D8 every 3 weeks for 2-6 cycles, then received tislelizumab 200 mg every 3 weeks for 2-17 cycles. In GC group, pts received cisplatin 70 mg/m2 D2, and gemcitabine 1000 mg/m2 D1 and D8 every 3 weeks for 2-6 cycles. The primary outcome was DFS, and secondary outcomes were OS and safety.
Results
The median follow-up was 17.7(2.1-38.3) months, totally 117 MIUC pts were analyzed, with a median age of 64 (34-85) years. 75.2% were male, 46.2% were UTUC, 20.5% were variant histology; pT3=58.9%, pT4=17.1%; pN+=52.1%. In T+GC group (n=68), the mean number of tislelizumab cycles was 4 and GC cycles was 2.7. In GC group (n=49), the mean number of GC cycles was 2.9. The T+GC group (n=68) had a significantly longer DFS compared with the GC group (n=49) (median DFS (95% CI): 19.1 (6.0-32.5) vs 8.4 (1.0-39.4) months, HR=0.172, P<0.001). While lymphovascular invasion pts had a lower probability of DFS (HR=22.1 (2.8-173.5), P=0.003). The OS was longer in the T+GC group (n=68) (median OS (95% CI): 20.1(6.0-32.5) vs 12.2(1.5-39.4) months, P=0.186). Longer follow-up was required to determine the OS benefits in T+GC group. Grade 1-2 immune related adverse events including pruritus (n=10), ALT/AST increased (n=8), hyperthyroidism (n=5) and hyperglycaemia (n=3).
Conclusions
Our data demonstrated effectiveness of tislelizumab combined with GC as adjuvant therapy for pT3/4 and pN+ MIUC pts in real world.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sun Yat-sen University Cancer Center.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
551P - Real-world incidence and outcomes of immune-related adverse events in NSCLC patients
Presenter: Andrea Knox
Session: Poster Display
Resources:
Abstract
552P - TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in Asian patients (pts) with previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)
Presenter: Yasushi Goto
Session: Poster Display
Resources:
Abstract
553P - Preceding plasma EGFR vs upfront tissue NGS for advanced NSCLC in the Chinese population: A single centre experience in Hong Kong
Presenter: Janet Du
Session: Poster Display
Resources:
Abstract
554P - Comparison of the analytical performance of endobronchial ultrasound-guided transbronchial needle aspiration and other sampling methods for the Oncomine Dx target test: An observational study
Presenter: Kazuhito Miyazaki
Session: Poster Display
Resources:
Abstract
555P - Quality of life in patients with stage IV non-small cell lung cancer and the influence of druggable mutations over time: A prospective, territory-wide study in Hong Kong
Presenter: Jason C S Ho
Session: Poster Display
Resources:
Abstract
556P - Results from the phase I study on efficacy and safety of iruplinalkib (WX-0593) for anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients who received prior second-generation ALK tyrosine kinase inhibitors (TKIs)
Presenter: xuezhi Hao
Session: Poster Display
Resources:
Abstract
557P - Longitudinal plasma proteomic profiling of EML4-ALK positive lung cancer receiving ALK-TKIs therapy
Presenter: Shasha Wang
Session: Poster Display
Resources:
Abstract
558P - Treatment duration and adherence of brigatinib as second-line treatment after crizotinib for ALK+ NSCLC in South Korea
Presenter: Jeong Eun Lee
Session: Poster Display
Resources:
Abstract
559P - Comprehensive survey of AACR GENIE database revealed a wide range of TMB distribution among all three classes (I, II, III) of BRAF mutated NSCLC
Presenter: Zhaohui Arter
Session: Poster Display
Resources:
Abstract
560P - Triple-targeted therapy of dabrafenib, trametinib and osimertinib for the treatment of acquired BRAF V600E mutation after progression on EGFR-TKIs in advanced EGFR-mutant NSCLC
Presenter: Chengdi Weng
Session: Poster Display
Resources:
Abstract